193 related articles for article (PubMed ID: 28267263)
1. Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.
Geyer FC; Burke KA; Piscuoglio S; Ng CKY; Papanastasiou AD; Marchiò C; Selenica P; Edelweiss M; Murray MP; Brogi E; Soslow RA; Rubin BP; Norton L; Reis-Filho JS; Weigelt B
Mol Oncol; 2017 Aug; 11(8):913-926. PubMed ID: 28267263
[TBL] [Abstract][Full Text] [Related]
2. Uterine adenosarcomas are mesenchymal neoplasms.
Piscuoglio S; Burke KA; Ng CK; Papanastasiou AD; Geyer FC; Macedo GS; Martelotto LG; de Bruijn I; De Filippo MR; Schultheis AM; Ioris RA; Levine DA; Soslow RA; Rubin BP; Reis-Filho JS; Weigelt B
J Pathol; 2016 Feb; 238(3):381-8. PubMed ID: 26592504
[TBL] [Abstract][Full Text] [Related]
3. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
[TBL] [Abstract][Full Text] [Related]
4. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
[TBL] [Abstract][Full Text] [Related]
5. DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation.
Bean GR; Anderson J; Sangoi AR; Krings G; Garg K
Mod Pathol; 2019 Feb; 32(2):280-289. PubMed ID: 30266945
[TBL] [Abstract][Full Text] [Related]
6. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
7. Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors.
Momeni Boroujeni A; Kertowidjojo E; Wu X; Soslow RA; Chiang S; Da Silva EM; Weigelt B; Chui MH
Mod Pathol; 2022 Nov; 35(11):1684-1694. PubMed ID: 36138078
[TBL] [Abstract][Full Text] [Related]
8. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS
Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048
[TBL] [Abstract][Full Text] [Related]
9. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
Garcia-Dios DA; Levi D; Shah V; Gillett C; Simpson MA; Hanby A; Tomlinson I; Sawyer EJ
Br J Cancer; 2018 Jan; 118(2):277-284. PubMed ID: 29315289
[TBL] [Abstract][Full Text] [Related]
10. Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma.
Yoon JY; de Kock L; Stewart CJR; McCluggage WG; Foulkes WD; Clarke BA; Rouzbahman M
Cancer Treat Res Commun; 2021; 27():100363. PubMed ID: 33838572
[TBL] [Abstract][Full Text] [Related]
11. Uterine Adenosarcoma.
Pinto A; Howitt B
Arch Pathol Lab Med; 2016 Mar; 140(3):286-90. PubMed ID: 26927725
[TBL] [Abstract][Full Text] [Related]
12. MED12 exon 2 mutations in phyllodes tumors of the breast.
Nagasawa S; Maeda I; Fukuda T; Wu W; Hayami R; Kojima Y; Tsugawa K; Ohta T
Cancer Med; 2015 Jul; 4(7):1117-21. PubMed ID: 25865354
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscapes of breast fibroepithelial tumors.
Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
[TBL] [Abstract][Full Text] [Related]
14. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2015 Jul; 152(2):305-12. PubMed ID: 26093648
[TBL] [Abstract][Full Text] [Related]
16. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions.
Chen PH; Bossuyt V; Reisenbichler E
Hum Pathol; 2021 Feb; 108():68-75. PubMed ID: 33245988
[TBL] [Abstract][Full Text] [Related]
17. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
[TBL] [Abstract][Full Text] [Related]
18. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
[TBL] [Abstract][Full Text] [Related]
19. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
Ng CCY; Md Nasir ND; Loke BN; Tay TKY; Thike AA; Rajasegaran V; Liu W; Lee JY; Guan P; Lim AH; Chang KTE; Gudi MA; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Yip GWC; Bay BH; Tan P; Teh BT; Tan PH
Mod Pathol; 2021 Jul; 34(7):1320-1332. PubMed ID: 33727697
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
